Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Mistakes disrupt budgets and derail goals. Explore how small oversights impact finances and how to recalibrate for stable, predictable spending.
27,871 articlesPfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Bittensor's $52 million annual subsidy governs the network's top subnets, creating an 'income desert' that could unra...
BNB slips on a brief pullback, but longer-term momentum remains constructive as rising moving averages and a quiet re...
Wave Life Sciences slumped after INLIGHT readouts failed to establish WVE-007 as a solo obesity treatment, triggering...
AMD delivered a strong Q1 FY2026, prompting a broad uprising in analyst targets. Nine firms boosted price targets as ...
The FDA approved two fruit-flavored vape lines from a Los Angeles company, a notable policy reversal that comes as po...
Two funds track the same Nasdaq-100 index, but a lower expense ratio gives Invesco NASDAQ 100 ETF a quiet advantage f...
Coldwell Banker Real Estate LLC appoints Mary Lee Blaylock as president of Coldwell Banker Affiliates, underscoring a...
Circle announces a $222 million Arc token presale at a $3 billion FDV, drawing major investors as quarterly revenue g...
A high-stakes clash between Ray Dalio and Michael Saylor drives a renewed bitcoin price analysis as markets digest Bi...
Bitcoin Suisse has secured Bermuda regulatory licenses to operate regulated digital asset management and investment a...
The S&P 500 reached a new record as Bitcoin faced renewed selling pressure. Analysts say the divide underscores a liq...